Phase
Condition
Diabetes And Hypertension
High Blood Pressure (Hypertension)
High Blood Pressure (Hypertension - Pediatric)
Treatment
Amlodipine
Olmesartan
Amlodipine/Olmesartan
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion criteria
Age 18 up to and including 75 years
24 hours systolic blood pressure 130-164 (corresponding with grade 1-2 hypertension), without the use of blood pressure lowering agents (at screening for patients without pre-treatment or after 4 week wash-out of antihypertensive medication for subjects using a single antihypertensive agent at screening)
Indication for antihypertensive therapy according to the 2023 European Society of Hypertension Guidelines for the management of arterial hypertension
Subject is not treated with antihypertensive drugs or is treated with a single antihypertensive drug.
Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons: 1 year postmenopausal, surgically sterile, or willing to use an acceptable method of contraception (oral contraceptives, approved contraceptive implants, long-term injectable contraception, intrauterine devices, or tubal ligation are allowed.)
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Treatment with 2 or more antihypertensive drugs < 3 months before inclusion. It is not allowed to stop medication for study purposes in subjects treated with 2 or more anti-hypertensive drugs.
Known diagnosis of secondary hypertension to an identifiable cause other than treated sleep apnea (e.g., hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome, coarctation of the aorta, uncontrolled hyper- or hypothyroidism and intracranial tumor)
Use of VEGF inhibitors, calcineurin inhibitors, glucocorticosteroids, erythropoietin stimulation agents, daily use of NSAID's
Use of MDMA, methamphetamine, cocaine
Use of glycyrrhetinic acid containing products , i.e. liquorice, specific herbal teas, <4 weeks before inclusion. (If patients are willing to stop the intake of glycyrrhetinic acid containing products for the duration of the trial, they can be rescreened after 4 weeks of stopping glycyrrhetinic acid containing products)
Use of potassium containing supplements
Concurrent use of medication or a supplement with significant drug interaction with study medication. Special attention is warranted for amlodipine which is metabolized by Cyp3A4. Subjects using strong inhibitors or inducers of Cyp3A4 are excluded from participation in this trial. A list of strong inhibitors and inducers is provided in Addendum 1 of this protocol. For information on possible drug interactions we refer to the website of Lexi-Interact Online (Lexicomp® Drug Interactions - UpToDate (doctorabad.com): https://doctorabad.com/UpToDate/d/di.htm).
History of myocardial infarction, angina pectoris
History of atrial fibrillation
History of severe valvular or structural heart disease (excluding left ventricular hypertrophy)
History of NYHA class III or IV heart failure or known reduced left ventricular function (ejection fraction (EF) <30%)
History of cerebrovascular accident or transient ischemic attack
History of hypertensive crisis
History of liver failure
History of skin cancer
History of gout
Current hyperparathyroidism
Current biliary tract obstruction
Pregnancy
Life expectancy < 1 year
Known side effect or contra-indication to treatment with calcium channel blockers
Known side effect or contra-indication to treatment with angiotensin II receptor blockers
Known side effect or contra-indication to treatment with thiazide diuretics
Arm circumference > 46 cm
Sodium level outside reference range at screening visit
Potassium level outside reference range at screening visit
Calcium level outside reference range at screening visit
eGFR < 50 ml/min/1,73m2
Use of loop diuretics.
Study Design
Connect with a study center
Radboudumc
Nijmegen,
NetherlandsActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.